LEXINGTON, Mass., Oct. 7, 2014 (GLOBE NEWSWIRE) -- T2 Biosystems (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that the T2Candida® Panel and the T2Dx® Instrument will be included in four oral and poster presentations during IDWeek 2014™. The annual meeting will take place October 8-12, 2014, at the Pennsylvania Convention Center in Philadelphia.
Last month, T2 Biosystems received market authorization from the U.S. Food and Drug Administration (FDA) for its first two products, T2Candida Panel and the T2Dx Instrument, for the direct detection of Candida species in human whole blood specimens from patients with symptoms of, or medical conditions predisposing the patient to, invasive fungal infections.
The schedule for IDWeek presentations is as follows:
| Title: | Opportunistic Mold Infections 2014: Progress and Challenges |
| Date & Time: | Wednesday, October 8, 2014, 9 – 11:00 a.m. |
| Session: | Satellite Symposium |
| Location: | Room 118-ABC |
| Presenters: | Dimitrios P. Kontoyiannis, M.D., Sc.D., FACP, FIDSA; Kieren A. Marr, M.D., FIDSA; Peter G. Pappas, M.D., FACP (Moderator); George R. Thompson, M.D. |
| Title: | Fungal Infections in the ICU – Another View |
| Date & Time: | Saturday, October 11, 2014, 8:30 – 10:00 a.m. |
| Session: | Symposia |
| Location: | Room 103-ABC |
| Presenter: | Susan Hadley, M.D., FIDSA, Tufts University School of Medicine and Eleftherios Mylonakis, M.D., Ph.D., Rhode Island Hospital |
| Title: | Intra-Abdominal Candidiasis: Description Of An Under-Appreciated Disease And A Case Report Of Rapid Diagnosis By Whole Blood T2Candida Assay |
| Date & Time: | Saturday, October 11, 2014, 12:30 – 2 p.m. |
| Session: | Poster Abstract Session, Fungal Infections; Abstract # 1447 |
| Location: | IDExpo Hall BC |
| Presenter: | Cornelius (Neil) J. Clancy, M.D., University of Pittsburgh |
| Title: | Frontiers in Infectious Diseases Diagnostics: Molecular Diagnostics for Infectious Diseases: State of the Science |
| Date & Time: | Sunday, October 12, 2014, 8 – 10:00 a.m. |
| Session: | Closing Plenary Session |
| Location: | Terrace Ballroom – I, II, III, IV |
| Speaker: | Angela M. Caliendo, M.D., Ph.D., FIDSA; Alpert Medical School of Brown University and Rhode Island Hospital |
In addition, T2 Biosystems' chief medical officer Mike Pfaller, M.D., will give in-booth presentations on T2Candida and T2Dx titled "Antifungal Stewardship: Rapid Diagnostics to Address the Resistance Crisis" on October 9, 10 and 11 at 12:15 p.m. To participate, or for more information, please visit the T2 Biosystems booth #632.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA authorized products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to work with the medical community to bring such products to hospitals, physicians and patients. These and other important factors discussed under the caption "Risk Factors" in the Company's final prospectus filed with the Securities and Exchange Commission, pursuant to Rule 424(b) of the Securities Act of 1933, as amended, on August 7, 2014, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.